Clinical Trial: Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With

Brief Summary: The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.

Detailed Summary:
Sponsor: Ipsen

Current Primary Outcome: Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0) [ Time Frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months) ]

The primary objective was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of children maintaining a regression or stabilisation of sexual maturity (based on Tanner breast [girls] or genital [boys] pubertal stage) until end of study. Study treatment lasted until end of the therapeutic period; visits for Months 36 and 48 were optional since a child may have already finished the study at a prior visit. The Final Visit only occurred if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Results are presented only for percentage of girls with regression or stabilisation of Tanner breast pubertal stage (n=34). Since only one boy was included in the study, results for this outcome measure were listed only and no statistical analysis was performed. Please also note additional post-hoc analysis for regression or stabilisation of Tanner breast pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.


Original Primary Outcome: Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]

Current Secondary Outcome:

  • Percentage of Patients With a Suppressed Luteinizing Hormone (LH) Response to Gonadotropin-Releasing Hormone (GnRH) Test [ Time Frame: Months -6, 0 and 36 ]
    A suppressed LH response to the GnRH test was defined as a stimulated peak of LH ≤3 international units per litre (IU/L). Percentage of patients who had a suppressed LH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
  • Levels of Oestradiol in Girls or Testosterone in Boys Both Measured by Radioimmunoassay (RIA) [ Time Frame: Months -6, 0, 12, 36 and Final Visit (up to 63 months) ]
    Mean levels of oestradiol in girls or testosterone in boys are reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
  • Percentage of Patients With a Suppressed Follicle Stimulating Hormone (FSH) Response to GnRH Test [ Time Frame: Months -6, 0 and 36 ]
    A suppressed FSH response to the GnRH test was defined as a stimulated peak of FSH ≤3 IU/L. Percentage of patients who had a suppressed FSH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
  • Body Mass Index (BMI) for Chronological Age Variation [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]
    Mean changes of BMI from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • BMI Standard Deviation (SD) Score for Chronological Age Variation [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]
    Mean changes of BMI SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • Auxological Parameters Variations: Height SD Score [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]
    Mean changes of height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • Auxological Parameters Variations: Growth Velocity SD Score [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]
    Mean changes of growth velocity SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • Auxological Parameters Variations: Weight Variation [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]
    Mean changes of weight from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • Predicted Adult Height SD Score [ Time Frame: Months -6, 0, 12 and Final Visit (up to 63 months) ]
    Mean change of predicted adult height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented. Also note that data for this endpoint was analysed for girls only.
  • Bone Age Maturation [ Time Frame: Months -6, 0 and Final Visit (up to 63 months) ]
    Mean change in difference between bone age and chronological age from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • Percentage of Girls With a Uterine Length < 36 Millimetres (mm) [ Time Frame: Months -6, 0, 12, 24, 36 and Final Visit (up to 63 months) ]
    Percentage of girls who had a uterine length < 36 mm are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
  • Percentage of Children With a Stabilisatio

    Original Secondary Outcome:

    • LH response to GnRH tests [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]
    • Levels of oestradiol in girls or testosterone in boys both measured by RIA [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]
    • FSH response to GnRH test [ Time Frame: M12, M24, M36 M48 and final visit (if applicable) ]
    • BMI and BMI SD score for the chronological age variation [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]
    • Auxological parameters variations (height, growth velocity, weight variation) [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]
    • Bone age variation [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]
    • Proportion of girls with an uterine length < 36 mm [ Time Frame: M12, M24, M36, M48 and final visit (if applicable) ]


    Information By: Ipsen

    Dates:
    Date Received: May 28, 2009
    Date Started: April 2008
    Date Completion:
    Last Updated: March 17, 2017
    Last Verified: March 2017